

Abattis Issues Common Shares

Vancouver, BC – June 2, 2016 - Abattis Bioceuticals Corp. (the "**Company**" or "**Abattis**") (OTCQX: ATTFB) (CSE: ATT), announces that on May 31, 2016 the Company issued 2,621,500 common shares as compensation for services to consultants, directors and employees of the Company, no legend was required on any of the issued shares.

The Company issued 1,500,000 common shares pursuant to a debt conversion agreement whereby the Company converted \$75,000 of debt owed at a deemed price of \$0.05 per common share. The Company issued 1,019,171 units pursuant to a debt conversion agreement whereby the Company converted \$50,958.56 of debt owed at a deemed price of \$0.05 per unit. Each unit consists of one common share and one share purchase warrant of the Company exercisable at \$0.07 per common share for a period of 24 months from the date of issuance. The debt conversions required a four month and a day legend on the shares.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company that aggregates, incubates, integrates, and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets – some of which will contain cannabinoid compounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Rene David"

Rene David, CFO/COO

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.